David Hung
CIK: 0001310880
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jun 3, 2026NVCR
NovoCure Ltd
Award(A)Direct11.6K shares- - Jun 2, 2026NVCR
NovoCure Ltd
Sale(S)Direct2.9K shares at avg. $15.77$46K - Feb 27, 2026NUVB
Nuvation Bio Inc.
Award(A)DirectStock Option (Right to Buy)
2M shares- - Jun 16, 2025NUVB
Nuvation Bio Inc.
Purchase(P)Direct500K shares at avg. $1.79$894K - Jun 4, 2025NVCR
NovoCure Ltd
Award(A)Direct11.2K shares- - Jun 3, 2025NVCR
NovoCure Ltd
Sale(S)Direct999 shares at avg. $17.30$17K - Apr 7, 2025NUVB
Nuvation Bio Inc.
Purchase(P)Direct300K shares at avg. $1.63$488K - Apr 4, 2025NUVB
Nuvation Bio Inc.
Purchase(P)Direct200K shares at avg. $1.66$333K - Feb 28, 2025NUVB
Nuvation Bio Inc.
Award(A)DirectStock Option (Right to Buy)
2M shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 3, 2026 |  NVCR NovoCure Ltd | Award(A) | 11,610 | - | $0 | Direct |
| Jun 2, 2026 | NVCR NovoCure Ltd | Sale(S) | 2,945 | $15.77 | $46,445 | Direct |
| Feb 27, 2026 |  NUVB Nuvation Bio Inc. | Award(A) Stock Option (Right to Buy) | 1,995,012 | - | - | Direct |
| Jun 16, 2025 | NUVB Nuvation Bio Inc. | Purchase(P) | 500,000 | $1.79 | $893,500 | Direct |
| Jun 4, 2025 | NVCR NovoCure Ltd | Award(A) | 11,215 | - | - | Direct |
| Jun 3, 2025 | NVCR NovoCure Ltd | Sale(S) | 999 | $17.30 | $17,280 | Direct |
| Apr 7, 2025 | NUVB Nuvation Bio Inc. | Purchase(P) | 300,000 | $1.63 | $487,500 | Direct |
| Apr 4, 2025 | NUVB Nuvation Bio Inc. | Purchase(P) | 200,000 | $1.66 | $332,720 | Direct |
| Feb 28, 2025 | NUVB Nuvation Bio Inc. | Award(A) Stock Option (Right to Buy) | 2,000,000 | - | - | Direct |
1-9 of 9 transactions
About Hung David
Hung David (SEC CIK 0001310880) files insider reports with the SEC as Director of NovoCure Ltd (NVCR) and PRESIDENT AND CEO of Nuvation Bio Inc. (NUVB).
Signal8 holds 8 ownership filings by Hung David, all Form 4s, filed between Mar 4, 2025 and Jun 5, 2026. Those filings report 9 transactions, from Feb 28, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hung David's filings is in WAYNE, PA.
Recent filings by Hung David
- Jun 3, 2026: Grant or award of NVCR shares (Form 4, code A).
- Jun 2, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Feb 27, 2026: Grant or award of NUVB derivative securities (Form 4, code A).
- Jun 16, 2025: Open-market purchase of NUVB shares (Form 4, code P).
- Jun 4, 2025: Grant or award of NVCR shares (Form 4, code A).
Other insiders filing for NovoCure Ltd (NVCR)
- Puri Michal Nath, Chief Human Resources Officer
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director